While many big Chinese pharma companies are looking at the US market to take their first international steps, Tianjin Pharma, a state-owned group and the local partner in GlaxoSmithKline's joint venture in China, has decided to begin its planned global expansion in Southeast Asia.
Tianjin Pharma's Indonesian JV a stepping stone to international expansion
While many big Chinese pharma companies are looking at the US market to take their first international steps, Tianjin Pharma, a state-owned group and the local partner in GlaxoSmithKline's joint venture in China, has decided to begin its planned global expansion in Southeast Asia.
More from Cardiovascular
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Therapeutic Category
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.